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Background: The long noncoding RNA MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) is
described as a potential biomarker for NSCLC (non-small cell lung cancer). Diagnostic biomarkers need to be
detectable in easily accessible body fluids, should be characterized by high specificity, sufficient sensitivity, and
robustness against influencing factors. The aim of this study was to evaluate the performance of MALAT1 as a blood
based biomarker for NSCLC.
Results: MALAT1 was shown to be detectable in the cellular fraction of peripheral human blood, showing different
expression levels between cancer patients and cancer-free controls. For the discrimination of NSCLC patients from
cancer-free controls a sensitivity of 56% was calculated conditional on a high specificity of 96%. No impact of tumor
stage, age, gender, and smoking status on MALAT1 levels could be observed, but results based on small numbers.
Conclusions: The results of this study indicate that MALAT1 complies with key characteristics of diagnostic
biomarkers, i.e., minimal invasiveness, high specificity, and robustness. Due to its relatively low sensitivity MALAT1
might not be feasible as a single biomarker for the diagnosis of NSCLC in the cellular fraction of blood.
Alternatively, MALAT1 might be applicable as a complementary biomarker within a panel in order to improve the
entire diagnostic performance.
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Lung cancer is the leading cause of cancer death world-
wide [1] with NSCLC (non-small cell lung cancer) as the
most prominent subgroup accounting for approximately
80% of all lung cancer cases. Commonly, the disease is
detected in late stages resulting in short survival rates,
whereas for patients with early-stage lung cancer longer
survival rates could be observed [2]. Thus, the detection
of lung cancer in early stages when clinical symptoms
have not yet occurred appears to be a promising oppor-
tunity to decrease mortality, because in more cases a
curative therapy might become possible.* Correspondence: weber@ipa-dguv.de
†Equal contributors
1Institute for Prevention and Occupational Medicine of the German Social
Accident Insurance, Institute of the Ruhr-Universität Bochum (IPA),
Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany
Full list of author information is available at the end of the article
© 2013 Weber et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orIn principal, biomarkers should be feasible for the de-
tection of cancer in early stages. Thus, a major aim in
cancer research is the identification of proper bio-
markers. Key characteristics of diagnostic biomarkers
among others are: (i) minimally-invasive to measure the
biomarker in easily accessible body fluids, (ii) high speci-
ficity to avoid false-positive results in cancer-free indi-
viduals, (iii) sufficient sensitivity to detect the tumors,
and (iv) robustness against potential influencing factors.
In recent years biomarker research focused on noncod-
ing RNAs (ncRNAs), in particular microRNAs (miRNAs).
MiRNAs are small RNA molecules with a length of ~ 22
nucleotides (nt), playing a central role in the regulation of
gene expression [3] and acting as tumor suppressors or
oncogenes in cancer [4]. Several studies show the feasibil-
ity of using miRNAs as biomarkers in body fluids for the
diagnosis of lung cancer [5-8]. However, there is a lack ofLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of the study groups comprising
patients with NSCLC (non-small cell lung cancer),
subdivided into AdCa (adenocarcinoma) and SqCC
(squamous cell carcinoma), and cancer-free controls
Total NSCLC AdCa SqCC Controls
N 70 45 21 24 25
Gender Male 48 30 15 15 18
Female 22 15 6 9 7
Age (years) Median 69 68 68 67 71
Range 54 - 84 54 - 83 57 - 83 54 - 81 56 - 84
Smoking status Ever 64 44 20 24 20
Never 6 1 1 0 5
Tumor stage I/II 3 0 3
III/IV 42 21 21
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cation of miRNAs as biomarkers [9]. Thus, the discovery
of alternative or complementing biomarkers is essential.
In addition to miRNAs, long noncoding RNAs
(lncRNAs) are a promising alternative within the group
of ncRNAs. LncRNAs are commonly described as RNA
molecules with a length > 200 nt, playing regulatory and
structural roles in biological processes. As lncRNAs are
implicated as tumor suppressors and oncogenes [10], they
might be feasible as diagnostic biomarkers [11]. Currently,
only few lncRNAs have been described as candidate bio-
markers in human body fluids [10]. HULC (highly up-
regulated in liver cancer) is highly expressed in hepatocel-
lular carcinoma patients and detectable in human blood
[12]. PCA3 (prostate cancer gene 3) is detectable in urine
of prostate cancer patients, showing high accuracy [13]. In
addition, MALAT1 (metastasis-associated lung adenocar-
cinoma transcript 1) might be a candidate biomarker for
NSCLC [14]. MALAT1 is a well-described lncRNA widely
expressed in normal tissues [15]. In several human carcin-
omas MALAT1 was shown to be upregulated [16], par-
ticularly in early-stage metastasizing NSCLC.
The aim of this study was the evaluation of MALAT1
as a blood-based biomarker for NSCLC. The expression
of MALAT1 was measured in the cellular fraction of per-
ipheral human blood and the expression levels of




The study was designed according to rules guarding pa-
tient privacy and with the approval from the ethics com-
mittee of the Ruhr-Universität Bochum (No. 3217–08).
All participants provided written informed consent.
The cancer group of 45 NSCLC patients consisted of
21 patients with AdCa (adenocarcinoma) and 24 patients
with SqCC (squamous cell carcinoma). Participants were
recruited at the HELIOS Clinic Emil von Behring, Berlin,
Germany. Tumor staging was performed according to
the TNM classification of malignant tumors [17]. Cancer
patients had not been treated by surgery, chemotherapy,
or radiation therapy before blood collection. The control
group of 25 cancer-free subjects was drawn from the
Heinz Nixdorf Recall study, a population-based cohort
of elderly subjects [18]. Characteristics of the study
groups are summarized in Table 1. Detailed subject
characteristics are listed in Additional file 1.
RNA isolation
Peripheral blood samples were collected from each partici-
pant in 9.0 ml S-Monovette EDTA gel tubes (Sarstedt,
Nümbrecht, Germany) and centrifuged (2000 x g for
10 minutes) within 30 minutes after collection. Thecellular fraction was separated from plasma and stored
frozen until RNA isolation.
Samples were thawed at room temperature and RNA
isolation including DNase I treatment was performed
from 0.5 ml of the cellular fraction using the RiboPure
Blood Kit according to the manufacturers’ instructions
(Life Technologies, Darmstadt, Germany).
Quantitative real-time PCR (qRT-PCR)
TaqMan assays (Life Technologies) were used for quanti-
tative expression analyses of MALAT1 (Hs00273907_s1)
as potential biomarker and of GAPDH (Hs99999905_m1),
HPRT1 (Hs02800696_m1), and RPLP0 (Hs99999902_m1)
as potential reference genes for normalization. Quantita-
tive real-time PCR (qRT-PCR) was performed using a
7900 HT Fast Real-Time PCR System (Life Technologies).
For the reverse transcription reaction 12 μl RNA and
for the PCR reaction 5 μl cDNA were used as templates.
Samples were analyzed in duplicate and non-template
controls were included. For cycle threshold (Ct) estima-
tion a fixed threshold of 0.2 was used. Ct values > 35
were considered to be under the detection limit [19]
and marked as 35 for analysis [20]. Raw Ct values are
presented in Additional file 1.
The performance of potential references was analyzed
utilizing RefFinder [21], a web-based comprehensive
tool (www.leonxie.com/referencegene.php), including
the four commonly used algorithms geNorm [22],
NormFinder [23], BestKeeper [24], and comparative
ΔCt method [25], to evaluate the most stable reference
across study groups. As the geometric mean (GM) of
several reference genes is more reasonable than a single
reference gene [22], the GM of potential references was
calculated. Normalized MALAT1 levels were expressed
as ΔCt, with ΔCt = Ct(MALAT1) - Ct(Reference).
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Median and inter-quartile range (IQR) were used to de-
scribe the distribution of MALAT1 levels. Groups were
compared using the non-parametric Kruskal-Wallis test
for continuous variables. Sensitivity and specificity of
MALAT1 were determined from receiver operating char-
acteristic (ROC) curves illustrating the performance of
MALAT1 to discriminate the studied groups. In brief,
NSCLC vs. controls, AdCa vs. controls, SqCC vs. controls,
and AdCa vs. SqCC were analyzed. The bootstrap proced-
ure (1000 runs) was used for internal validation of the esti-
mates in the ROC analyses.
Potential factors influencing MALAT1 levels were evalu-
ated using a linear regression model. Estimates were given as
β with 95% confidence intervals (CI) and p values. Here,
values of β > 0 indicate a negative association between the in-
fluencing factor and MALAT1 levels, values of β < 0 a posi-
tive association. Logistic regression modeling was performed
to estimate the odds ratio (OR) with 95% CI for detecting
NSCLC as a function of normalizedMALAT1 levels.
Statistical analyses were performed using SAS/STAT
and SAS/IML software, version 9.3 (SAS Institute Inc.,
Cary, NC).
Results
Expression stability of candidate references
The potential reference genes GAPDH, HPRT1, and
RPLP0 were measured in all samples from NSCLC pa-
tients and cancer-free controls. Using raw Ct values no
significant differences between NSCLC patients and con-
trols could be observed for GAPDH and HPRT1 in con-
trast to RPLP0 (p = 0.0002), (Figure 1). Thus, RPLP0 was
excluded from further evaluation as reference gene.
In order to identify the most stable reference across the
study groups RefFinder was used to rank the analyzedFigure 1 Scatter dot plots of raw Ct values of candidate
reference genes. GAPDH, HPRT1, and RPLP0 were measured in patients
with NSCLC (non-small cell lung cancer; N = 45) and cancer-free
controls (N = 25). Horizontal bars represent median and IQR. Groups
were compared using the Kruskal-Wallis test.references. Lowest rank represents the most stable refer-
ence and highest rank represents the least stable reference
(Table 2). The GM of GAPDH and HPRT1 was identified
as the most stable reference and used for normalization of
MALAT1.Distribution of MALAT1 in the study groups
Table 3 depicts the distribution of normalized MALAT1
levels in the study groups. The median normalized
MALAT1 value for NSCLC was −0.35 (IQR −1.34; 1.00),
for AdCa −0.59 (IQR −1.34; -0.25), and for SqCC −0.23
(IQR −1.31; 1.47), whereas for controls the median nor-
malized MALAT1 level was −2.07 (IQR −2.53; -0.83).
Differences of normalized MALAT1 levels between
cancer patients and cancer-free subjects were significant
for NSCLC vs. controls (p < 0.0001), AdCa vs. controls
(p = 0.0043), and SqCC vs. controls (p = 0.0001), whereas
the difference between AdCa and SqCC was not signifi-
cant (Figure 2).MALAT1 as biomarker of NSCLC
Using ROC analyses, for NSCLC patients and controls an
area under the curve (AUC) of 0.79 (95% CI 0.68 – 0.89),
(Figure 3A), for AdCa patients and controls an AUC of
0.75 (95% CI 0.59 – 0.90), (Figure 3B), for SqCC patients
and controls an AUC of 0.82 (0.70 – 0.94), (Figure 3C), and
for AdCa vs. SqCC an AUC of 0.58 (95% CI 0.42 – 0.76),
(Figure 3D), were calculated.
Sensitivity and specificity of normalized MALAT1 are
shown in Table 4, calculated due false-positive rates (FPR)
of 0% (no false-positive test), 4% (one false-positive test),
and 8% (two false-positive tests), and to the maximum
Youden’s Index (YI = sensitivity + specificity −1), respect-
ively. A FPR of 4%, representing 96% specificity, resulted
in 56% sensitivity for the discrimination of NSCLC from
controls. The sensitivity to discriminate SqCC from con-
trols is higher (63%) than the sensitivity to discriminate
AdCa from controls (48%). A FPR of 8% (92% specificity)Table 2 Results of reference analysis using RefFinder [21]










geNorm GM* & GAPDH HPRT1
NormFinder GM* GAPDH HPRT1
BestKeeper HPRT1 GM* GAPDH
Comparative ΔCt method GM* GAPDH HPRT1
*Geometric mean (GM) was calculated from GAPDH and HPRT1.
Table 3 Distribution of normalized MALAT1 levels by median and inter-quartile range (IQR) stratified by potential
influencing factors
Total Controls NSCLC AdCa SqCC
N Median IQR N Median IQR N Median IQR N Median IQR N Median IQR
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Figure 2 Scatter dot plots of MALAT1 levels in NSCLC (N = 45),
AdCa (N = 21), SqCC (N = 24), and cancer-free controls (N = 25).
Expression values were normalized by the geometric mean of
GAPDH and HPRT1 and expressed as ΔCt. Horizontal bars represent
median and IQR. Groups were compared using the Kruskal-Wallis
test. NSCLC: non-small cell lung cancer, AdCa: adenocarcinoma,
SqCC: squamous cell carcinoma.
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of 0% (100% specificity) resulted in lowest sensitivities for
the discrimination of controls from patients with NSCLC
(47%), AdCa (38%), or SqCC (54%). Use of the maximum
YI leads to an increase in sensitivity to 81% only for AdCa
vs. controls, but specificity decreased to 64%. For the dis-
crimination of AdCa from SqCC a FPR of 5% (95% specifi-
city, one false-positive test) resulted in 8% sensitivity and a
FPR of 10% (90% specificity, two false-positive tests) re-
sulted in 21% sensitivity, whereas using the maximum YI
resulted in 33% sensitivity and 86% specificity.
ROC analyses on 1000 bootstrap samples resulted in
similar cutoffs, sensitivities, and specificities of MALAT1
in comparison to the original analyses. The calculated
95% CI regarding NSCLC vs. controls and SqCC vs. con-
trols indicate a good precision of this assessment,
whereas AdCa vs. controls the 95% CI shows a less pre-
cision (Additional file 2).
The application of logistic regression models revealed a
two-fold increased risk of detecting NSCLC per normalized
Figure 3 Receiver operating characteristics (ROC) curves of normalized MALAT1. The area under curve (AUC) was determined for MALAT1 of
(A) NSCLC (non-small cell lung cancer) patients and controls, (B) AdCa (adenocarcinoma) patients and controls, (C) SqCC (squamous cell
carcinoma) patients and controls, and (D) AdCa patients and SqCC patients.
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1.26 - 2.83) without adjustment and 2.03 (95% CI 1.30-
3.16) with adjustment for gender, age and smoking
status.
Potential factors influencing MALAT1
The influence of tumor characteristics on MALAT1
levels is shown in Table 5. MALAT1 is not affected by
tumor size, metastasis status or lymph node status.
The impact of potential influencing factors on the ex-
pression levels of MALAT1 are shown in Table 6. NSCLC
showed a significant 1.63-fold (95% CI 0.75 – 2.51) de-
crease of MALAT1 (p = 0.0003), whereas the factors gen-
der, age, and smoking status showed no impact on the
MALAT1 levels in human blood.
Discussion
NSCLC is commonly detected in late stages of the dis-
ease. Biomarkers have the potential to detect cancer at
early stages, facilitating an earlier and therefore morecurative therapy that ideally results in decreased mortality.
In NSCLC, Gutschner et al. showed that MALAT1 regu-
lates the expression of several metastasis-associated genes,
e.g. CDCP1 (CUB domain containing protein 1) and
GPC6 (glypican 6), indicating a major role of MALAT1 in
disease progression [26]. Additionally, it was suggested
thatMALAT1 might also regulate other important cellular
processes in lung cancer [26]. Thus, MALAT1 is a candi-
date biomarker for NSCLC [14].
For quantitative expression analysis of messengerR-
NAs (mRNAs) and miRNAs qRT-PCR is considered to
be the gold standard [27] and the same might be true
for lncRNAs. However, to produce reliable data in qRT-
PCR assays the use of appropriate reference genes for
normalization is an important issue [28] and candidate
reference genes need to be tested prior to application
[29]. As no information regarding lncRNAs as references
were accessible, mRNAs were selected as potential refer-
ences. HPRT1 and RPLP0 are well-described reference
genes for analyses in NSCLC tissues [30] and GAPDH
Table 4 Sensitivity and specificity of normalized MALAT1 and number of true-positive, true-negative, false-positive,
and false-negative tests, calculated for different false positive rates (FPR), i.e., none, one, and two false-positive tests















FPR = 0% −0.24 47 100 21 25 0 24
FPR = 4% −0.41 56 96 25 24 1 20
FPR = 8% −0.42 56 92 25 23 2 20
Maximum
YI
−0.41 56 96 25 24 1 20
AdCa vs. controls FPR = 0% −0.05 38 100 8 25 0 13
FPR = 4% −0.35 48 96 10 24 1 11
FPR = 8% −0.42 48 92 10 23 2 11
Maximum
YI
−1.44 81 64 17 16 9 4
SqCC vs. controls FPR = 0% −0.24 54 100 13 25 0 11
FPR = 4% −0.41 63 96 15 24 1 9
FPR = 8% −0.42 63 92 15 23 2 9
Maximum
YI
−0.41 63 96 15 24 1 9
AdCa vs. SqCC FPR = 0% 3.37 8 100 2 21 0 22
FPR = 5% 2.76 8 95 2 20 1 22
FPR = 10% 1.91 21 90 5 19 2 19
Maximum
YI
1.32 33 86 8 18 3 16
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However, in this study RPLP0 seems to be no feasible
reference which is in agreement with Falkenberg et al.,
showing that RPLP0 is not appropriate as reference gene
in human blood samples [31]. In this study, GAPDH and
HPRT1 were suitable reference genes, particularly the
GM of GAPDH and HPRT1 showed the best reference
performance. This is in accordance with Ulivi et al.,
using GAPDH and HPRT1 for normalization of mRNAs
in blood samples of NSCLC patients and controls [32].
One key characteristic of proper diagnostic biomarkers
is the need to be detectable in easily accessible body fluids
like peripheral blood. In this study MALAT1 was mea-
sured in the cellular fraction of human blood, showingTable 5 Analysis of tumor characteristics influencing MALAT1
NSCLC
β 95% CI p va
Intercept −1.23 −3.49; 1.03
Tumor size (Reference: I/II) III/IV 1.06 −1.28; 3.39 0.36
Intercept −0.15 −1.11; 0.80
Metastasis status (Reference: M0) M1 −0.14 −1.36; 1.07 0.81
Intercept −0.20 −2.48; 2.08
Lymph node status (Reference: N0) N1-N3 −0.04 −2.40; 2.32 0.97
Values of β > 0 indicate a negative association between the analyzed factor and MAthat this matrix is in principle appropriate for the analysis
of lncRNAs. Comparable results for the usability of the
cellular blood fraction were shown for miRNAs [33,34].
Commonly, the cellular fraction obtained during plasma
preparation is discarded, but it might be reasonable to col-
lect this matrix in biobanks for subsequent biomarker
discovery.
In this study, a significant downregulation of MALAT1
in NSCLC patients in comparison to cancer-free con-
trols was shown. Comparable results were achieved by
Zhang et al., showing a downregulation of MALAT1 in
patients with hepatocellular carcinomas [35]. However,
MALAT1 was implicated to play an oncogenic role [10]
and upregulation of MALAT1 was observed in severallevels in human blood
AdCa SqCC
lue β 95% CI p value β 95% CI p value
−1.23 −3.41; 0.96
70 1.52 −0.82; 3.85 0.1911
−0.22 −3.24; 2.81 −0.14 1.15; 0.86
43 −0.46 −3.64; 2.72 0.7655 0.65 −0.98; 2.26 0.4158
0.24 −4.02; 4.51 −0.42 −3.20; 2.35
14 −0.92 −5.29; 3.45 0.6654 0.57 −2.32; 3.47 0.6860
LAT1 levels, values < 0 a positive association.
Table 6 Analysis of potential factors influencing MALAT1
levels in human blood




Group (Reference: controls) NSCLC 1.63 0.75;
2.51
0.0004
Gender (Reference: male) Female 0.22 −0.66;
1.10
0.6210








Statistically significant changes are marked in bold.
Values of β > 0 indicate a negative association between analyzed factor and
MALAT1, values < 0 a positive association.
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ferences might be caused by the paradigm that in fact
MALAT1 is expressed ubiquitously but fulfills tissue-
specific functions depending on the cellular environment
[36]. Commonly, MALAT1 is analyzed in tissues [14-16],
whereas in this study and the study of Zhang et al. [35]
MALAT1 was detected in blood. BecauseMALAT1 was de-
tected in the cellular fraction of blood, it is unlikely to be
directly produced by the tumor tissue. Its downregulation
in blood cells may be an indirect effect of the tumor, e.g.,
on the immune system. The source of MALAT1 in the cel-
lular fraction of blood remains unclear. Theoretically, it
might originate from leucocytes altered by the tumor. How-
ever, further analyses are needed to evaluate the origin of
MALAT1 in human blood. Very recently, it was shown that
MALAT1 was detectable in plasma of patients with gastric
or prostate cancer [37,38]. Thus, it would be reasonable to
analyze MALAT1 in plasma of NSCLC patients instead of
the cellular fraction, because the presence of MALAT1 in
plasma might be a direct effect of the tumor, e.g., release of
lncRNA-containing extracellular vesicles [39].
Tani et al. showed that the stability of MALAT1 varied
in various cell types and indicated that the half-life of
MALAT1 is shorter than the median half-life of mRNA
[40]. Such decay of MALAT1 might also prevail in blood
cells. It is well known that systems like PAXgene, Tempus,
and RNAlater stabilize mRNAs and miRNAs in whole
blood samples [41-43]. Thus, the performance of the assay
was additionally tested in a few available blood samples
stabilized by PAXgene or RNAlater. In the stabilized blood
samples MALAT1 is detectable at lower Ct values corre-
sponding to larger quantities (data not shown). The results
implicate that the use of stabilization systems might be
meaningful for lncRNA analyses in blood. However, this
assumption needs to be verified in more detail.
Regarding the key characteristics of an obligatory high
specificity and a sufficiently high sensitivity of diagnosticbiomarkers, the candidate biomarker MALAT1 does not
fulfill both criteria. Generally, in screening cohorts a high
specificity is needed to avoid an unacceptably high num-
ber of false-positive tests that would result in psycho-
logical pressure and needless intervention for the patients.
Thus, the sensitivity of candidate biomarkers should be
calculated at a fixed high specificity level [44]. In regard to
the relatively small study group the specificity of 96% is
quite high, particularly as this corresponds to only one sin-
gle false-positively tested control. On the other hand, the
calculated sensitivity is too low (56%) for the use of
MALAT1 as a single biomarker for the diagnosis of
NSCLC, particularly for the subtype AdCa (48%). How-
ever, lower sensitivity could be balanced by the use of sev-
eral biomarkers in a panel. Theoretically, in an optimal
panel every single biomarker is characterized by suffi-
ciently high sensitivity and the necessary high specificity,
perfectly complement each other in order to obtain super-
ior diagnostic performance [45]. Thus, it might be reason-
able to verify MALAT1 in combination with other
biomarkers in larger study groups to improve the entire
diagnostic performance of the biomarker panel. However,
for the discrimination of AdCa and SqCC, a sensitivity of
only 8% precludes MALAT1 as a biomarker for the differ-
ential diagnosis of NSCLC subtypes.
Bootstrap analysis showed that the calculated cutoffs,
sensitivities, and specificities remain stable, indicating
that the calculated values are appropriate for the dis-
crimination of patients and controls.
Regarding the fourth key characteristic of diagnostic
biomarkers, the results indicate that MALAT1 values in
blood are not correlated with tumor size, metastasis sta-
tus, or lymph node status. However, more cases of early-
stage metastasizing NSCLC need to be analyzed in sub-
sequent studies because this study comprises only three
cases with tumor stage T1 or T2. Additionally, MALAT1
seems to be relatively independent from common influ-
encing factors like age, gender, and smoking status, indi-
cating the robustness of the candidate biomarker. These
observations are in agreement with MALAT1 expression
in tissue [46]. However, it has to be clarified if other po-
tential influencing factors from the multitude of bio-
logical, preanalytical, and analytical factors show an
impact on MALAT1 levels in human blood.
Conclusions
MALAT1 could be detected in peripheral blood, showing
different expression levels between NSCLC patients and
cancer-free controls. It was shown that MALAT1 com-
plies with key characteristics of diagnostic biomarkers,
being minimally-invasive, exhibiting high specificity, and
robustness. On the contrary, the observed sensitivity is
too low for the use of MALAT1 as a single biomarker
for the diagnosis of NSCLC using the cellular fraction of
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verify the performance of MALAT1 as a complementary
biomarker within a panel in larger studies including
more cases of early-stage metastasizing NSCLC.
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